Published 11 minutes ago • loading... • Updated 2 days ago
Pfizer Will No Longer Sell Hormone Replacement Therapy in Canada
Pfizer said the decision follows an internal review and is not tied to safety concerns, while tablet stocks may last until mid-2027.
On Thursday, Pfizer Canada confirmed it will stop selling the hormone replacement therapy Premarin following an internal review, stating the decision is not related to safety, efficacy, or quality concerns.
The vaginal cream has been in shortage since June, while existing inventories of 0.3 mg, 0.625 mg, and 1.25 mg strength tablets are expected to last until about mid-2027.
Premarin Intravenous, used for hospital treatment of abnormal uterine bleeding, remains unaffected, and Pfizer Canada advises patients to consult healthcare providers before changing hormone replacement treatments.
This discontinuation exacerbates existing supply constraints in Canada, where Health Canada reported intermittent shortages of estradiol transdermal patches by Bayer and Sandoz expected to continue until early 2027.
While the decision applies only to Canada, Pfizer continues selling Premarin products in the United States, Australia, New Zealand, and Singapore, declining to comment on supply situations in other markets.